S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
BREAKING: Tiny biotech successfully treats blindness (Ad)
How major US stock indexes fared Friday, 9/29/2023
MarketBeat Week in Review – 9/25 - 9/29
BREAKING: Tiny biotech successfully treats blindness (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
BREAKING: Tiny biotech successfully treats blindness (Ad)
How major US stock indexes fared Friday, 9/29/2023
MarketBeat Week in Review – 9/25 - 9/29
BREAKING: Tiny biotech successfully treats blindness (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
BREAKING: Tiny biotech successfully treats blindness (Ad)
How major US stock indexes fared Friday, 9/29/2023
MarketBeat Week in Review – 9/25 - 9/29
BREAKING: Tiny biotech successfully treats blindness (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
BREAKING: Tiny biotech successfully treats blindness (Ad)
How major US stock indexes fared Friday, 9/29/2023
MarketBeat Week in Review – 9/25 - 9/29
BREAKING: Tiny biotech successfully treats blindness (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
NASDAQ:PDSB

PDS Biotechnology (PDSB) Stock Forecast, Price & News

$5.05
+0.02 (+0.40%)
(As of 09/29/2023 ET)
Compare
Today's Range
$4.88
$5.10
50-Day Range
$4.80
$6.40
52-Week Range
$2.89
$13.65
Volume
486,708 shs
Average Volume
317,363 shs
Market Capitalization
$155.89 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.00

PDS Biotechnology MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
236.6% Upside
$17.00 Price Target
Short Interest
Bearish
14.80% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.02mentions of PDS Biotechnology in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.54) to ($1.72) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.59 out of 5 stars

Medical Sector

885th out of 970 stocks

Pharmaceutical Preparations Industry

416th out of 449 stocks


PDSB stock logo

About PDS Biotechnology (NASDAQ:PDSB) Stock

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. The company is developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma. In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.

PDSB Price History

PDSB Stock News Headlines

PDS Biotech to Present at the LD Micro Main Event XVI
WARNING: Seven millionaires to trigger sudden market panic?
The next major selloff could be just days away…And seven powerful (yet completely unknown) insiders will be behind it all – and help corporate executives make a killing as it plays out. Here’s the full story.
WARNING: Seven millionaires to trigger sudden market panic?
The next major selloff could be just days away…And seven powerful (yet completely unknown) insiders will be behind it all – and help corporate executives make a killing as it plays out. Here’s the full story.
PDS Biotechnology (NASDAQ: PDSB)
PDS Biotechnology (PDSB) Gets a Buy from Noble Financial
Q2 2023 PDS Biotechnology Corp Earnings Call
The Prognosis For PDS Biotechnology
PDS Biotechnology Earnings Preview
See More Headlines
Receive PDSB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PDS Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

PDSB Company Calendar

Last Earnings
8/14/2023
Today
9/30/2023
Next Earnings (Estimated)
11/13/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PDSB
Employees
26
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$17.00
High Stock Price Forecast
$21.00
Low Stock Price Forecast
$12.00
Forecasted Upside/Downside
+236.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-40,850,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.55 per share

Miscellaneous

Free Float
27,781,000
Market Cap
$155.88 million
Optionable
Not Optionable
Beta
1.93
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Dr. Frank K. Bedu-Addo Ph.D. (Age 58)
    Pres, CEO & Director
    Comp: $854.1k
  • Mr. Matthew C. Hill CPAMr. Matthew C. Hill CPA (Age 54)
    CFO, Principal Financial & Accounting Officer
    Comp: $504.09k
  • Ms. Lauren V. Wood M.D. (Age 63)
    Chief Medical Officer
    Comp: $568.5k
  • Dr. Joe J. Dervan
    VP of R&D
  • Dr. Gregory L. Conn Ph.D. (Age 68)
    Chief Scientific Officer
  • Ms. Deanne Randolph
    VP of Commercial Devel. & Head of Investor Relations
  • Mr. Spencer Brown J.D. (Age 53)
    Sr. VP & Gen. Counsel
  • Ms. Nathalie Riebel
    Sr. VP of Clinical Operations
  • Mr. Sanjay Zaveri
    Sr. VP of Bus. Devel.
  • Ms. Janetta Trochimiuk (Age 60)
    Controller













PDSB Stock - Frequently Asked Questions

Should I buy or sell PDS Biotechnology stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PDS Biotechnology in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PDSB shares.
View PDSB analyst ratings
or view top-rated stocks.

What is PDS Biotechnology's stock price forecast for 2023?

3 Wall Street research analysts have issued 1 year price targets for PDS Biotechnology's stock. Their PDSB share price forecasts range from $12.00 to $21.00. On average, they predict the company's share price to reach $17.00 in the next year. This suggests a possible upside of 236.6% from the stock's current price.
View analysts price targets for PDSB
or view top-rated stocks among Wall Street analysts.

How have PDSB shares performed in 2023?

PDS Biotechnology's stock was trading at $13.20 at the start of the year. Since then, PDSB stock has decreased by 61.7% and is now trading at $5.05.
View the best growth stocks for 2023 here
.

When is PDS Biotechnology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our PDSB earnings forecast
.

How were PDS Biotechnology's earnings last quarter?

PDS Biotechnology Co. (NASDAQ:PDSB) issued its earnings results on Monday, August, 14th. The company reported ($0.37) EPS for the quarter, hitting the consensus estimate of ($0.37).

What other stocks do shareholders of PDS Biotechnology own?
What is PDS Biotechnology's stock symbol?

PDS Biotechnology trades on the NASDAQ under the ticker symbol "PDSB."

How do I buy shares of PDS Biotechnology?

Shares of PDSB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is PDS Biotechnology's stock price today?

One share of PDSB stock can currently be purchased for approximately $5.05.

How much money does PDS Biotechnology make?

PDS Biotechnology (NASDAQ:PDSB) has a market capitalization of $155.88 million. The company earns $-40,850,000.00 in net income (profit) each year or ($1.62) on an earnings per share basis.

How can I contact PDS Biotechnology?

PDS Biotechnology's mailing address is 25B Vreeland Road, Florham Park NJ, 07932. The official website for the company is www.pdsbiotech.com. The company can be reached via phone at (800) 208-3343, via email at ir@edgetherapeutics.com, or via fax at 908-790-1212.

This page (NASDAQ:PDSB) was last updated on 9/30/2023 by MarketBeat.com Staff

My Account -